What Is AOD-9604?
AOD-9604 emerged from decades of research into the structure-function relationships of human growth hormone. In the 1990s, Professor Frank Ng and colleagues at Monash University in Melbourne, Australia, identified that the C-terminal fragment of HGH (residues 176 to 191) was responsible for the hormone's lipolytic activity, while the growth-promoting and insulin-antagonistic effects were mediated by different structural regions.
By synthesizing this 16-amino-acid fragment and substituting a tyrosine for the native phenylalanine at position 176, the team created AOD-9604, a peptide that could stimulate fat breakdown without the metabolic complications of full-length growth hormone. The amino acid sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, with a disulfide bridge between the two cysteine residues at positions 7 and 14.
Metabolic Pharmaceuticals Ltd., an Australian biotechnology company, licensed the technology and advanced AOD-9604 through clinical development between 2001 and 2007. The peptide has a molecular formula of C₇₈H₁₂₃N₂₃O₂₃S₂, a molecular weight of approximately 1,815 g/mol, and CAS number 221231-10-3.The proposed benefits of AOD-9604 include:
- Stimulation of lipolysis (fat breakdown) in adipose tissue
- Inhibition of lipogenesis (new fat formation)
- No elevation of IGF-1 levels or interference with glucose metabolism
- No growth-promoting or insulin-antagonistic effects
- Potential support for cartilage repair (emerging research)
How It Works
Lipolytic Mechanism
AOD-9604 stimulates lipolysis, the hydrolysis of stored triglycerides into free fatty acids and glycerol, in adipose tissue. The primary mechanism involves upregulation of beta-3 adrenergic receptors (beta-3 AR), the major lipolytic receptor in fat cells. In obese mice, both HGH and AOD-9604 increased the suppressed levels of beta-3 AR mRNA to levels comparable with those in lean animals, restoring normal lipolytic responsiveness.
The importance of this pathway was confirmed in knockout studies: beta-3 AR knockout mice were completely unresponsive to the lipolytic effects of both HGH and AOD-9604, demonstrating that the beta-3 adrenergic pathway is essential to the peptide's fat-metabolizing activity.Anti-Lipogenic Effects
In addition to promoting fat breakdown, AOD-9604 appears to inhibit lipogenesis, the de novo synthesis of fatty acids. In vitro studies using isolated adipocytes showed that AOD-9604 simultaneously increased fat oxidation rates while reducing new fat formation. This dual action, stimulating lipolysis while inhibiting lipogenesis, was considered a distinguishing feature of the peptide in early research.
Cartilage Regeneration
More recent preclinical research has explored AOD-9604's effects on cartilage and connective tissue. In vitro studies demonstrated that AOD-9604 promotes proteoglycan and collagen production in chondrocyte cultures and enhances the differentiation of adipose-derived mesenchymal stem cells into bone-forming cells.
A 2015 rabbit model of osteoarthritis found that intra-articular injection of AOD-9604, particularly when combined with hyaluronic acid, improved cartilage integrity and reduced joint degradation compared to controls. These findings are preliminary and have not been replicated in human clinical trials.
Distinction from Full Growth Hormone
The critical advantage of AOD-9604 over exogenous HGH was its selective activity profile. Across six clinical trials involving 893 participants, AOD-9604 did not increase serum IGF-1 levels, did not impair glucose tolerance or carbohydrate metabolism, and did not produce the fluid retention, joint pain, or insulin resistance associated with full-length growth hormone therapy. No anti-AOD-9604 antibodies were detected in any tested participants, indicating low immunogenicity.